Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Median PS Value is ₹0.00 as of Jul. 19, 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 545 Drug Manufacturers companies, Rubicon Research ranks worse than 183486.06% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Rubicon Research's Median PS Value or its related term are showing as below:
NSE:RUBICON's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Rubicon Research (NSE:RUBICON) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Rubicon Research's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1439.60
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research Median PS Value Related Terms
Rubicon Research Median PS Value Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Median PS Value Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Rubicon Research's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹80.611.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Median PS Value of ₹0.00 as of Jul. 19, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #999999 out of 545 companies in the Drug Manufacturers industry.
Is Rubicon Research's Median PS Value too high?
Rubicon Research's current Median PS Value is ₹0.00. Based on the distribution chart, Rubicon Research ranks #999999 out of 545 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Median PS Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #999999 out of 545 companies for Median PS Value. This places Rubicon Research in the lower half of its industry. The industry median Median PS Value is 0.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Median PS Value is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Median PS Value of ₹0.00. The current Median PS Value is ₹0.00. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Median PS Value is ₹0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
